Onyx Pharmaceuticals (ONXX) VP and Chief Medical Officer Resigns
More News related to ONXX
- Baird Starts Onyx Pharmaceuticals (ONXX) at Outperform
- Boenning & Scattergood Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Neutral
- Quarterly Changes to the NASDAQ Q-50 Index
- Onyx Pharmaceuticals to Present at the Goldman Sachs 30th Annual Global Healthcare Conference
- Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
In a Form 8-K, Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) today said that its Executive VP and Chief Medical Officer, Henry Fuchs, announced his resignation from the company, effective immediately.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oral anticancer therapies designed to prevent cancer cell proliferation and angiogenesis by inhibiting proteins that signal or support tumor growth in the United States and internationally.
Related Categories
Management ChangesStocks Mentioned
-0.85Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
